Cencora OUTPH Insights

  1. International Reference Pricing (IRP): Foundations, Shifts, And What To Do Next 4/17/2026

    As global pricing reforms evolve and policies gain traction, stakeholders must critically reassess the role of International Reference Pricing in balancing affordability, access, and incentives for innovation.

  2. Streamlining European Expansion With Integrated PV, Regulatory, And Commercial Expertise 4/17/2026

    See how a single-provider model integrated pharmacovigilance with regulatory and commercialization support to support a scalable, audit-ready system that strengthened compliance and freed internal resources for growth.

  3. How Automation, Analytics, And AI Can Assist Safety Signal Management 3/4/2026

    See how advanced analytics and human-in-the-loop systems are helping safety teams move beyond traditional disproportionality methods to manage complex biologics and growing case volumes.

  4. Best Practices For Managing The Logistics And Distribution Of CGTs 2/23/2026

    Site infrastructure, formulary timelines, and storage capabilities create barriers between approval and patient access. Planning for these operational realities separates successful launches from stalled ones.

  5. Navigating EU Regulatory Challenges With Cell And Gene Therapies 2/23/2026

    EU regulatory changes affecting advanced therapies demand new approaches to scientific advice, evidence generation, and health technology assessment for cell and gene therapy developers.

  6. The Value Of Real-World Evidence In Canadian Drug Commercialization 2/18/2026

    Leveraging real-world evidence (RWE) across the product lifecycle enables manufacturers to fill the evidence gap beyond RCTs to help guide local commercial strategic planning and market access strategy.

  7. Digitized Solutions To Increase Visibility And Streamline Communication Between A PSP And Manufacturer 2/18/2026

    When email-based escalation management creates compliance and visibility gaps, a centralized digital solution helps manufacturer and PSP teams act faster and with greater accountability.

  8. Digital Twins And Hybrid Models In Biologics Production: A Model Comparison 2/17/2026

    Hybrid models outperform classical approaches in bioreactor prediction. See how combining mechanistic knowledge with machine learning builds process understanding that holds up beyond training conditions.

  9. As eCTD 4.0 Adoption Inches Forward, A New ICH Guideline Puts It To The Test 2/17/2026

    Regulatory submissions are changing as eCTD 4.0 advances and the updated M4Q guideline reshapes how quality data is structured, cross-referenced, and reviewed across product lifecycles.

  10. Unlock The Potential Of Pharmacovigilance Outsourcing 2/17/2026

    Outsourcing pharmacovigilance can reduce overhead, strengthen compliance, and free teams to focus on innovation. Examine what a well-structured global PV model actually looks like in practice.